Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
Cyclopamine is a naturally derived plant-based steroid alkaloid that has attracted significant attention for its role in regulating the Hedgehog (Hh) signaling pathway. As a key regulatory mechanism for embryonic development and tissue homeostasis, the Hedgehog signaling pathway is abnormally activated and closely linked to the occurrence and progression of various tumors, especially prominent in malignant tumors such as basal cell carcinoma (BCC). As a selective smoothed (SMO) receptor inhibitor, cyclopamine can effectively block abnormal activation of the Hh signaling pathway, demonstrating potential antitumor activity.
This paper aims to systematically review the chemical structure and physicochemical properties of cyclopamine, plant origin and extraction methods, pharmacological activity and mechanism of action, druggability evaluation, pharmacokinetic characteristics, as well as its prospects and challenges in clinical application, aiming to provide scientific reference and theoretical support for the fields of natural product pharmacology and targeted tumor therapy.
Cyclobamine has a molecular formula of C27H41NO2, a molecular weight of 411.62, and a CAS number of 4449-51-8. Its structure belongs to steroid alkaloids, featuring a typical steroid framework and a nitrogen-containing ring-like structure that imparts unique biological activity. The LogP value of cyclopamine is 4.5, indicating high lipid solubility, which is beneficial for cell membrane penetration and distribution in the body. The polar surface area (TPSA) is 38.69 Ų, and the number of hydrogen bond acceptors is 3, indicating moderate molecular polarity that facilitates binding to target proteins.
The physicochemical properties of cyclopamine enable it to effectively cross the blood-brain barrier (BBB), offering potential advantages in treating central nervous system diseases. Additionally, cyclopamine showed low risks of hepatotoxicity and cardiotoxicity in vitro experiments, showed no inhibitory effect on hERG channels, and Ames-induced mutagenic assays were negative, suggesting high safety and a solid druggability foundation.
Cyclobamine was first isolated from a wild plant native to North America—Veratrum californicum. This plant belongs to the Liliaceae family and has traditionally been used in folk herbal medicine to treat various diseases. The discovery of cyclopamine stems from studies of the plant's inducement of sheep fetal malformations (sheep head deformity), revealing its interference with the Hh signaling pathway in embryonic development.
The extraction of cyclopamine typically uses organic solvent extraction combined with column chromatography separation technology. The specific process includes:
1. Collect dried above-ground parts or rhizomes of Veratrum californicum and crush them.
2. Use methanol or ethanol for reflux extraction; after concentration, the extract is solvent-distributed to remove impurities.
3. Further purification by silica gel column chromatography or high-performance liquid chromatography (HPLC) yields high-purity cyclobamine.
In recent years, with the development of molecular biology and chemical synthesis technologies, methods for semi-synthesis and total synthesis of cyclopamine have gradually matured, providing technical support for large-scale production and structural optimization.
As a specific inhibitor of the Hedgehog signaling pathway, cyclopamine mainly exhibits pharmacological activity by antagonizing the SMO receptor. Cell experiment data show that cyclopamine inhibits SMO by an IC50 of about 46 nM, demonstrating highly effective targeting activity. By blocking SMO, cyclopamine effectively inhibits the activation of the downstream transcription factor GLI, thereby downregulating the expression of genes related to the Hh pathway.
Across various tumor models, cyclopamine exhibits significant anti-proliferative and pro-apoptotic effects, especially in basal cell carcinoma, pancreatic cancer, and certain brain tumors. Animal experiments have shown that cyclopamine can significantly slow tumor growth and reduce tumor burden. Additionally, cyclopamine has lower toxicity to normal cells and shows good selectivity.
In addition to its antitumor effects, the application of cyclopamine in models of embryonic developmental abnormalities also reveals its unique value in regulating the Hh signaling pathway, providing important tools for studying developmental biology and congenital disease mechanisms.
The Hedgehog signaling pathway plays a key role in embryonic development and tissue homeostasis, with core components including the ligand Hh protein, the receptor PTCH1, the signal transduction protein SMO, and the transcription factor GLI family. Under normal circumstances, PTCH1 inhibits SMO activity and blocks signal transduction; After the Hh ligand binds to PTCH1, it releases SMO inhibition and activates downstream signaling.
Cyclobamine blocks SMO activation by directly binding to SMO, thereby inhibiting the transmission of the Hh signaling pathway. Its main targets of action include:
- SMO (Smoothened): Cyclopamine acts as a selective inhibitor of SMO, blocking its conformational changes and signal transduction.
- PTCH1 (Patched1): As a negative regulatory receptor in the Hh pathway, PTCH1's dysfunction often leads to abnormal activation of SMO. Cyclopamine indirectly regulates PTCH1 signal feedback by inhibiting SMO.
- GLI1 (Glioma-associated oncogene homolog 1): As the main transcription factor of the Hh pathway, GLI1 expression and activity are regulated by SMO. Cyclopamine reduces GLI1 transcriptional activity by inhibiting SMO.
- SUFU (Suppressor of fused) and HHIP (Hedgehog-interacting protein): The effects of cyclopamine on these regulatory proteins are still under study, but their overall regulatory network is crucial for maintaining homeostasis in the Hh signaling pathway.
The molecular binding mechanism of cyclopamine has been partially resolved through crystallography and computational simulations, showing that it binds to the seven-order transmembrane domain of the SMO receptor, blocking SMO activation conformations and thereby inhibiting signal transduction.
The druggability parameters of cyclopamine indicate its promising potential for drug development. Its molecular weight (411.62) and LogP (4.5) meet the basic requirements for oral active drugs under the Lipinski rule, with moderate polarity and a number of hydrogen bond receptors favorable for target binding and bioavailability.
Cyclopamine can effectively cross the blood-brain barrier, suggesting its potential application in central nervous system diseases. In vivo toxicology evaluation showed cyclopamine showed no significant hepatotoxicity or cardiotoxicity, and hERG channel inhibition tests were negative, reducing the risk of arrhythmias. Ames-induced mutagenic test results were negative, indicating a low genotoxicity risk.
Pharmacokinetic studies have shown that cyclopamine is well absorbed orally, has a moderate plasma half-life, and is widely distributed in the body. Its metabolism mainly occurs through the hepatic cytochrome P450 enzyme system, with stable metabolites, and excretion mainly through bile and urine. Cyclopamine carries a low risk of drug interactions, but potential competition with other CYP450 substrates should be noted.
As one of the first discovered natural Hedgehog signaling pathway inhibitors, cyclopamine offers a new strategy for targeted treatment of basal cell carcinoma and related tumors. Abnormal activation of SMO in basal cell carcinoma is central to its pathogenesis. Cyclopamine selectively inhibits SMO, significantly suppressing tumor cell proliferation and invasion capacity. Preclinical research results are encouraging.
Currently, cyclopamine and its derivatives have entered multiple clinical trial phases to evaluate their efficacy and safety in tumors such as basal cell carcinoma, pancreatic cancer, and glioma. Some cyclopamine analogs, such as Vismodegib, have been approved by the FDA for the treatment of advanced basal cell carcinoma, demonstrating the clinical value of Hh pathway inhibitors.
Future research directions include:
- Optimize the pharmacokinetic properties of cyclopamine, improving bioavailability and tissue selectivity.
- Reduces drug resistance through structural modification, overcoming drug resistance in tumor cells.
- Explore the application of cyclopamine in other diseases related to abnormal Hh signaling, such as fibrosis and autoimmune diseases.
- Combine with other targeted drugs or immunotherapy to enhance anti-tumor effects and improve patient outcomes.
As a naturally derived Hedgehog signaling pathway inhibitor, cyclopamine shows broad application prospects in the field of targeted tumor therapy due to its unique chemical structure and significant biological activity. Its selective antagonism of SMO receptors provides new ideas and a pharmacological-based basis for the treatment of basal cell carcinoma and related malignancies. Despite challenges in pharmacokinetic optimization and resistance, research progress on cyclobamine and its derivatives continues to drive advances in natural product pharmacology and precision medicine.
In the future, combining modern drug design with molecular biology techniques, cyclopamine is expected to become an important drug for treating diseases related to the Hedgehog signaling pathway, bringing more benefits to patients.
